You are here

Kymriah

ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah

ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah

Fierce Pharma

Flag link:

Novartis’ CAR-T cancer drug available on NHS to young people

Novartis’ CAR-T cancer drug available on NHS to young people

Pharmaforum

refractory B-cell acute lymphoblastic leukemia

Flag link:

Insight: How Novartis built a ‘money-filled moat’ to market Kymriah

Insight: How Novartis built a ‘money-filled moat’ to market Kymriah

Biopharma Reporter

Flag link:

Novartis signs manufacturing deal for Kymriah in China

Novartis signs manufacturing deal for Kymriah in China

BioCentury

drug manufacturing

Flag link:

NICE rejects Novartis’ CAR-T in adult lymphoma

NICE rejects Novartis’ CAR-T in adult lymphoma

Pharmaforum

diffuse large B-cell lymphoma

Flag link:

Novartis CAR-T therapy snags UK coverage, cutting list price 23% from US

Novartis CAR-T therapy snags UK coverage, cutting list price 23% from US

Biopharma Dive

Flag link:

Novartis announces new €78m plant and 450 new jobs to manufacture Kymriah in EU

Novartis announces new €78m plant and 450 new jobs to manufacture Kymriah in EU

GoinPharma

acute lymphoblastic leukemia

Flag link:

Novartis wins a key OK for Kymriah, but continuing manufacturing woes hobble rollout — rival Gilead CAR-T breaks into Europe

Novartis wins a key OK for Kymriah, but continuing manufacturing woes hobble rollout — rival Gilead CAR-T breaks into Europe

Endpoints

drug manufacturing

Flag link:

Kymriah Manufacturing Issues Spell Trouble for Commercialization of Novartis CAR-T Therapy

Kymriah Manufacturing Issues Spell Trouble for Commercialization of Novartis CAR-T Therapy

Xtalks

drug manufacturing

Flag link:

Could an old Amgen-developed RA drug make CAR-T treatments safer?

Could an old Amgen-developed RA drug make CAR-T treatments safer?

Fierce Biotech

cytokine release syndrome

Flag link:

New approval sets up CAR-T showdown for Gilead, Novartis

New approval sets up CAR-T showdown for Gilead, Novartis

Biopharma Dive

Gilead Sciences

Flag link:

ICER declares costs of approved CAR-T therapies aligned with clinical benefit

ICER declares costs of approved CAR-T therapies aligned with clinical benefit

BioWorld

Gilead Sciences

Flag link:

Novartis’ Kymriah: The First Gene Therapy to Be Approved in the US

Novartis’ Kymriah: The First Gene Therapy to Be Approved in the US

Market Realist

acute lymphoblastic leukemia

Flag link:

Novartis could cut its Kymriah price to $160,000 and keep its profit margins: study

Novartis could cut its Kymriah price to $160,000 and keep its profit margins: study

Fierce Pharma

Flag link:

Patient Advocate Says Novartis' $475,000 Breakthrough Should Cost Just $160,000

Patient Advocate Says Novartis' $475,000 Breakthrough Should Cost Just $160,000

Forbes

Flag link:

Top 10 stories that had pharma execs talking

Top 10 stories that had pharma execs talking

Biopharma Dive

Bristol-Myers Squibb

Express Scripts

Kenneth Frazier

CVS Health Pfizer

Flag link:

Kymriah, Yescarta found ‘cost-effective’ in treating cancer, despite high price

Kymriah, Yescarta found ‘cost-effective’ in treating cancer, despite high price

Endpoints

Gilead Sciences

Flag link:

ASH 2017: CAR-T Wallops Blood Cancer

ASH 2017: CAR-T Wallops Blood Cancer

Motley Fool

Gilead Sciences

Juno Therapeutics

Flag link:

#ASH17: How does Novartis’ Kymriah DLBCL data stack up heading straight to a CAR-T showdown with Gilead?

#ASH17: How does Novartis’ Kymriah DLBCL data stack up heading straight to a CAR-T showdown with Gilead?

Endpoints

diffuse large B-cell lymphoma

Flag link:

Incoming Novartis CEO On $475,000 Cancer Therapy: 'No Question That The List Price Raises Eyebrows'

Incoming Novartis CEO On $475,000 Cancer Therapy: 'No Question That The List Price Raises Eyebrows'

Forbes

Flag link:

Pages